71184-20-8

Usage

InChI:InChI=1/C10H15N3O4/c11-7-1-2-13(10(17)12-7)6-3-5(4-14)8(15)9(6)16/h1-2,5-6,8-9,14-16H,3-4H2,(H2,11,12,17)/t5-,6?,8-,9+/m0/s1

Upstream product

• 405095-83-2 N-{[(1R,2S,3R,4R)-4-(tert-butoxymethyl)-2,3-(isopropylidenedioxy)cyclopentyl]aminocarbonyl}-3-methoxy-2-propenamide 
• 405095-84-3 (1'R,2'S,3'R,4'R)-1-[4'-(tert-butoxymethyl)-2',3'-(isopropylidenedioxy)cyclopentan-1'-yl]uracil 
• 415704-46-0 (1S,2S,3R,4R)-4-(tert-butoxymethyl)-2,3-(isopropylidenedioxy)-1-[(methylsulfonyl)oxy]-cyclopentane 
• 405095-81-0 (1R,2S,3R,4R)-1-azido-4-(tert-butoxymethyl)-2,3-(isopropylidenedioxy)cyclopentane 
• 405095-82-1 (1R,2S,3R,4R)-4-(tert-butoxymethyl)-2,3-(isopropylidenedioxy)-1-cyclopentanamine 
• 369647-25-6 (1S,2S,3R)-(-)-1-(2,2-dimethyl-5-vinyl-1,3-dioxolan-4-yl)-(S)-2-propen-1-ol 
• 223596-32-5 (1S,2S,3R,4R)-4-(tert-butoxymethyl)-2,3-(isopropylidenedioxy)-cyclopentan-1-ol 
• 223596-25-6 (3aR,6R,6aR)-6-(tert-butoxymethyl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-one 
• 115509-13-2 (3aR,6aR)-2,2-Dimethyl-3a,6a-dihydro-cyclopenta[1,3]dioxol-4-one 
• 126113-85-7 (1S,2S,3S)-2,2-dimethyl-6-vinyltetrahydrofuro[3,4-d]-1,3-dioxol-4-ol 
• 1070967-50-8 (1R,2S,3R,4R)-1-[4-(tert-butoxymethyl)-2,3-(isopropylidenedioxy)-cyclopentan-1-yl]-cytosine 
• 148473-12-5 (1R,5S,1'S)-5-(1',2'-Dihydroxyethyl)cyclopent-2-en-1-ol 
• 216441-13-3 (1S,2R)-2-Hydroxy-cyclopent-3-enecarbaldehyde 
• 188118-61-8 Acetic acid (1S,4R)-4-(4-benzoylamino-2-oxo-2H-pyrimidin-1-yl)-cyclopent-2-enylmethyl ester 

Downstream Products

• 180088-49-7 4-Amino-1-[(1R,2S,3R,4R)-4-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-2-(tert-butyl-dimethyl-silanyloxy)-3-hydroxy-cyclopentyl]-1H-pyrimidin-2-one 

Relevant academic research and scientific papers

(-)-Carbodine: Enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu)

Enantiomerically pure cyclopentyl cytosine [(-)-carbodine 1] was synthesized from d-ribose and evaluated for its anti-influenza activity in vitro in comparison to the (+)-carbodine, (±)-carbodine and ribavirin. (-)-Carbodine 1 exhibited potent antiviral activity against various strains of influenza A and B viruses.

CARBOCYCLIC COMPOUNDS AND METHODS FOR TREATING EMERGING DISEASES, INCLUDING INFLUENZA AND VENEZUELA EQUINE ENCEPHALITIS VIRUS

The present invention relates to the use of carbodine and 5-F carbodine and analogs thereof for use in the treatment or prophylaxis of influenza, in particular the H5N1 strain of Avian Influenza A virus or "bird flu" strain of influenza as well as the treatment or prophylaxis of Venezuela equine encephalitis virus or VEE.

An expeditious route to carbocyclic nucleosides: (-)-Aristeromycin and (-)-carbodine

The readily available bicyclic lactone (-)-1 was transformed into diacetate (-)-2 which served in an expeditious route to (-)-aristeromycin (3a) and (-)-carbodine (3b) in acceptable yields.

Synthesis and incorporation of carbocyclic nucleosides into a hammerhead ribozyme domain-RNase resistance and catalytic activity

A hammerhead ribozyme domain incorporating (-)-carbodine 8a and (-)-aristeromycin 8b at selected positions, manifests increased RNase resistance and exhibits significant catalytic activity.